SCHEMBL2907391

SCHEMBL2907391

CN1CCN(C(c2ccccc2)c2c[nH]nc2-c2ccccc2F)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 4/20 0.50
CHRM2 P08172 3/20 0.50
ADRA2A P08913 3/20 0.50
CHRM1 P11229 3/20 0.50
DRD1 P21728 3/20 0.50
DRD3 P35462 3/20 0.50
SLC6A3 Q01959 3/20 0.50
KCNH2 Q12809 3/20 0.50
CYP2D6 P10635 3/20 0.50
CHRM4 P08173 1/20 0.50
CHRM5 P08912 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
CHRM3 P20309 1/20 0.50
ADRA1D P25100 1/20 0.50
HTR2A P28223 1/20 0.50
HTR2C P28335 1/20 0.50
HRH1 P35367 1/20 0.50
HTR2B P41595 1/20 0.50
HRH3 Q9Y5N1 3/20 0.44
HTR1A P08908 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2905341 0.93 CHRM2 (0.43) OPRM1CHRM2ADRA2ACHRM1DRD1
SCHEMBL2908468 0.88 ALDH1A1 (0.41) OPRM1DRD3HRH3SMN1; SMN2ALDH1A1
SCHEMBL2906133 0.86 HSP90AA1 (0.43) OPRM1CYP2D6HRH3CYP2C19ALDH1A1
SCHEMBL2909897 0.84 KCNH2 (0.56) OPRM1CHRM2ADRA2ACHRM1DRD1
SCHEMBL2908936 0.80 HRH3 (0.39) OPRM1HRH3CYP2C19ALDH1A1CYP3A4
SCHEMBL2902536 0.80 OPRK1 (0.36) OPRM1KDM4EMEN1KMT2AOPRD1
SCHEMBL2905013 0.73 MEN1 (0.37) HTR2AHRH1TDP1KDM4EMEN1
SCHEMBL15992273 0.73 KCNH2 (0.35) OPRM1KCNH2CYP2D6HRH3CYP3A4
SCHEMBL2904863 0.73 CCR5 (0.34) OPRM1CHRM2ADRA2ACHRM1DRD1
SCHEMBL2904868 0.72 CHRM3 (0.37) CHRM3ALDH1A1MAPK1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed
EP-1611107-A1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GmbH (DE) 2006-01-04 EP disclosed
WO-2004089910-A1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A OPRM1 151/4885CHRM2 156/4885ADRA2A 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.